The Trump administration seems like its leaning toward allowing unapproved peptides.
So says The Washington Post. I’ve been writing about gray-market peptides in Optimizer, but this is a follow-up to July’s FDA hearings about whether compounding pharmacies should be allowed to sell unapproved peptides. It’s unclear which ones, and the timing could change, but the Post says this might give the administration a “political upside.” [Link: Trump administration paving way for temporary sale of some unapproved peptides | https://www.washingtonpost.com/health/2026/10/07/trump-administration-paving-way-temporary-sale-some-unapproved-peptides/ | The Washington Post]
